Familial hypercholesterolaemia in UK primary care: a Clinical Practice Research Datalink study of an under-recognised condition

Adeline Durand; Christopher Ll Morgan; Steven Tinsley; Elizabeth Hughes; Terry McCormack; Charlotte L Bitchell; Raquel Lahoz

doi:10.3399/BJGP.2023.0010

Familial hypercholesterolaemia in UK primary care: a Clinical Practice Research Datalink study of an under-recognised condition

Br J Gen Pract. 2024 Feb 7;74(740):e174-e182. doi: 10.3399/BJGP.2023.0010. Online ahead of print.

Authors

Adeline Durand¹, Christopher Ll Morgan², Steven Tinsley¹, Elizabeth Hughes³, Terry McCormack⁴, Charlotte L Bitchell², Raquel Lahoz⁵

Affiliations

¹ Novartis UK Ltd, London, UK.
² Pharmatelligence, Cardiff, UK.
³ Sandwell and West Birmingham Hospitals NHS Trust and University of Aston Medical School, Birmingham, UK.
⁴ Institute of Clinical and Applied Health Research, Hull York Medical School, Hull, UK.
⁵ Novartis AG, Basel, Switzerland.

Abstract

Background: Studies utilising genotyping methods report the prevalence of familial hypercholesterolaemia to be as high as one in 137 of the adult population.

Aim: To estimate the prevalence of familial hypercholesterolaemia measured by clinically coded diagnosis, associated treatments, and lipid measurements observed in UK primary care.

Design and setting: This was a retrospective analysis using the Clinical Practice Research Datalink (CPRD) GOLD database.

Method: Patients aged ≥18 years and actively registered on the index date (30 June 2018) formed the study cohort. Point prevalence of familial hypercholesterolaemia for 2018 was estimated overall and for each nation of the UK. Patients with familial hypercholesterolaemia were stratified into primary and secondary prevention groups, defined as those with/without a prior diagnosis of atherosclerotic cardiovascular disease. Prevalence estimates and extrapolations were replicated for these subgroups. Baseline demographic, lipid, and clinical characteristics for the prevalent cohort were presented.

Results: In total, 4048 patients with familial hypercholesterolaemia formed the study cohort. The estimated familial hypercholesterolaemia prevalence for the UK was 16.4 per 10 000 (95% confidence interval [CI] = 16.0 to 16.9). Of these, 2646 (65.4%) patients with familial hypercholesterolaemia had a recent prescription for lipid-lowering therapy. Mean lipid levels were lower for those treated with lipid-lowering therapy compared with those untreated: 5.34 mmol/L (SD 1.50) versus 6.25 mmol/L (SD 1.55) for total cholesterol and 3.15 mmol/L (SD 1.34) versus 3.96 mmol/L (SD 1.36) for low-level density lipoprotein cholesterol.

Conclusion: The estimated prevalence of familial hypercholesterolaemia was one in 608 of the population, less than expected from other studies, which may indicate that familial hypercholesterolaemia is under-recognised in UK primary care. Over one-third of diagnosed patients were undertreated and many did not achieve target goals, placing them at risk of cardiovascular events.

Keywords: familial hypercholesterolaemia; hypercholesterolaemia; lipid-lowering therapy; prevalence; primary health care.